Primary data from this phase I, first-in-human study investigating the safety, tolerability, and preliminary efficacy of SYK/FLT3 inhibitor mivavotinib, conducted in patients with advanced solid tumors or lymphoma malignancies, were previously reported [23]. Here, FLT3 is linked to lymphoma.